Clinical Trial Update: PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing PT001 MDI to Atrovent in moderate-to-severe chronic obstructive pulmonary disease has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Atrovent (ipratropium bromide)
• PT001 MDI

Snippet

Sponsor: Pearl Therapeutics, Inc. | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED | Results posted: 2017-06-08